Oral Cancer Screening in Dentistry
On this page
Direct answer
Oral cancer ranks among the commonest cancers in Indian men, and India carries an estimated one-third or more of the world's oral cancer burden, driven by smokeless tobacco and areca nut habits — areca nut is an IARC Group 1 carcinogen even without tobacco. Screening rests on oral visual examination (OVE): a systematic inspection and palpation of the high-risk sites, opportunistic at every dental visit and population-based under the National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Disease and Stroke (NPCDCS), whose operational framework recommends five-yearly oral screening of adults aged 30 and above. Any ulcer or lesion persisting beyond three weeks, and any suspicious potentially malignant disorder, goes to biopsy — incisional biopsy remains the confirmatory standard.
What you must remember
- Indian risk profile: gutka, khaini, paan with areca nut; areca nut alone is IARC Group 1 (carcinogenic to humans); tobacco plus alcohol act synergistically (multiplicative risk).
- High-risk subsites in Indian patients: buccal mucosa and retromolar trigone first (quid placement sites), then lateral tongue, floor of mouth and the soft palate complex.
- Potentially malignant disorders: leukoplakia (non-homogeneous and dysplastic lesions carry the higher risk), erythroplakia (highest risk — most biopsies already show severe dysplasia or carcinoma), oral submucous fibrosis (transformation quoted around 7–8 per cent in Indian series), lichen planus and proliferative verrucous leukoplakia.
- Oral submucous fibrosis — the Indian hallmark: areca-driven fibrosis with burning sensation, blanching, stiff mucosa, fibrous bands and progressive trismus; graded by interincisal opening.
- Screening technique (OVE): good light, systematic circuit of all subsites, palpation for induration, bimanual floor-of-mouth palpation, and neck node examination — achievable in two minutes.
- The three-week rule: any ulcer, red or white patch, or lump persisting beyond three weeks (or immediately if indurated) is referred for biopsy; weight loss, dysphagia, ear pain and numbness upgrade urgency.
- Adjuncts (toluidine blue vital staining, autofluorescence devices, brush cytology) help select biopsy sites or triage — none replaces scalpel biopsy and histopathology.
- NPCDCS operational framework (2016): oral, breast and cervical cancer screening at primary level — oral visual examination for adults 30 and above every five years with referral of suspicious findings; brief tobacco cessation advice (the 5A pattern) delivered at the same visit is among the highest-yield preventive acts a dentist performs.
Running the opportunistic screen
The screen is a two-minute circuit: lips and commissures, buccal mucosa both sides, vestibules, retromolar regions, hard and soft palate, tongue dorsum then lateral borders (grasp with gauze and rotate), ventral tongue and floor of the mouth bimanually, oropharynx, then any visible change and both neck chains.
Apply it to a 48-year-old with 20 years of gutka use and a white patch on the right buccal mucosa. Inspection: a 1.5 cm mixed white-and-red patch exactly at the site of quid placement. Palpation: leathery but not stony hard, with a subtle fibrous band and an interincisal opening of 28 mm — oral submucous fibrosis co-existing with a non-homogeneous leukoplakia, the higher-risk lesion. Toluidine blue retention can guide where the punch goes, but the decision is already biopsy: incisional biopsy of the worst area plus a second site, histopathology, and — on severe dysplasia or worse — referral to a head and neck unit. In the same minute comes the highest-yield intervention: structured tobacco cessation advice, because continued quid use drives both field change and recurrence.
How the exam frames it
Three framings dominate. "Which potentially malignant disorder has the highest transformation risk?" — erythroplakia, ahead of proliferative verrucous leukoplakia, non-homogeneous leukoplakia, OSMF and lichen planus, in rough descending order. "What does the national programme recommend?" — oral visual examination every five years from age 30 under the NPCDCS framework, delivered by trained health workers with referral of positives. "Why does India dominate global oral cancer statistics?" — the answer must name smokeless tobacco and areca nut (including its Group 1 classification and the not-innocent "tobacco-free" gutka), late presentation, and field cancerisation, which makes second primaries common. The persistent trap is calling a white patch "leukoplakia" and reviewing it indefinitely: the term commits you to biopsy to exclude dysplasia.
Frequently asked questions
What is oral visual examination and how often is it recommended?
Systematic inspection and palpation of all oral subsites with neck examination; under India's NPCDCS framework, every five years from age 30, and opportunistically at every dental visit.
Which potentially malignant disorder carries the highest risk of malignant transformation?
Erythroplakia — most biopsied erythroplakic lesions already show severe dysplasia or carcinoma, exceeding the risk of homogeneous leukoplakia, oral submucous fibrosis and lichen planus.
Why is areca nut considered carcinogenic even without tobacco?
The IARC classifies areca nut itself as a Group 1 human carcinogen; its alkaloids and tannins are genotoxic and drive fibrosis and malignant change, as in oral submucous fibrosis.
When should a suspicious oral lesion be biopsied rather than observed?
Immediately if indurated, ulcerated or growing; otherwise any lesion persisting beyond three weeks after removing obvious causes is biopsied, with toluidine blue guiding the site.